Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Black Diamond Therapeutics ( (BDTX) ).
On December 3, 2025, Black Diamond Therapeutics announced preliminary data from its Phase 2 trial of silevertinib in frontline non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations, showing a 60% objective response rate and 86% CNS response rate. The company plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed glioblastoma (GBM) patients in the first half of 2026, with preliminary data expected in 2028, highlighting the potential of silevertinib as a targeted therapy for EGFR-altered GBM.
The most recent analyst rating on (BDTX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Black Diamond Therapeutics stock, see the BDTX Stock Forecast page.
Spark’s Take on BDTX Stock
According to Spark, TipRanks’ AI Analyst, BDTX is a Underperform.
Black Diamond Therapeutics is currently a high-risk investment due to its weak financial performance characterized by zero revenue and negative cash flow. The technical analysis suggests continued volatility, and the valuation highlights typical challenges of early-stage biotech firms. However, the recent strategic partnership with Servier offers potential long-term benefits. The overall score reflects the significant financial challenges and current market sentiment, with potential upside from successful execution of its strategic initiatives.
To see Spark’s full report on BDTX stock, click here.
More about Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company focused on developing MasterKey therapies targeting families of oncogenic mutations in cancer patients. Their therapies aim to address a wide range of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and penetrate the brain to treat central nervous system diseases.
Average Trading Volume: 1,013,521
Technical Sentiment Signal: Buy
Current Market Cap: $214.8M
For an in-depth examination of BDTX stock, go to TipRanks’ Overview page.